China Resources Pharmaceutical Group Limited

Informe acción SEHK:3320

Capitalización de mercado: HK$34.1b

Salud financiera de hoja de balance de China Resources Pharmaceutical Group

Salud financiera controles de criterios 5/6

China Resources Pharmaceutical Group tiene un patrimonio de accionistas total de CN¥97.1B y una deuda total de CN¥74.9B, lo que sitúa su ratio deuda-patrimonio en 77.1%. Sus activos y pasivos totales son CN¥266.4B y CN¥169.2B respectivamente. El BAIT de China Resources Pharmaceutical Group es de CN¥11.6B, por lo que su ratio de cobertura de intereses es de 8.3. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥33.1B.

Información clave

77.1%

Ratio deuda-patrimonio

CN¥74.87b

Deuda

Ratio de cobertura de intereses8.3x
EfectivoCN¥33.08b
PatrimonioCN¥97.12b
Total pasivoCN¥169.24b
Activos totalesCN¥266.36b

Actualizaciones recientes sobre salud financiera

Recent updates

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Dec 19
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥197.6B) de 3320 superan a sus pasivos a corto plazo (CN¥144.0B).

Pasivo a largo plazo: Los activos a corto plazo de 3320 (CN¥197.6B) superan a sus pasivos a largo plazo (CN¥25.2B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 3320 (43%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 3320 ha pasado de 91.5% a 77.1% en los últimos 5 años.

Cobertura de la deuda: La deuda de 3320 está bien cubierta por el flujo de caja operativo (24.4%).

Cobertura de intereses: Los pagos de intereses de la deuda de 3320 están bien cubiertos por el BAIT (8.3x cobertura).


Hoja de balance


Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/12/22 23:29
Precio de las acciones al final del día2024/12/20 00:00
Beneficios2024/06/30
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

China Resources Pharmaceutical Group Limited está cubierta por 20 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited